“…Three translocations were identified (PAX5-ETV6, 56,57 PAX5-FOXP1, PAX5-ZNF521), each of which fuses the DNA-binding paired domain of PAX5 to key functional domains of partner genes that have known or putative roles in lymphoid development or oncogenesis. [58][59][60][61][62] These translocations are predicted to disrupt normal activity of PAX5 (and possibly the partner gene), and in luciferase reporter assays using a CD19 reporter, the fusions were found to act as competitive inhibitors of normal PAX5 transactivating activity. Subsequent studies have identified additional PAX5 fusions in ALL, involving multiple partner genes including ASXL1, AUTS2, BRD1, C20orf112, DACH1, ELN, HIPK1, JAK2, KIF3B, LOC392027, PML, POM121 and SLCO1B3.…”